Regulation & law · 15/05/2003Updated: 10/17/2026 · 1 min read

DEA Withdraws Proposed Rule to Remove Fenfluramine from Controlled Substances Act

Summary

The Drug Enforcement Administration (DEA) has withdrawn a proposed rule to remove fenfluramine from schedule IV of the Controlled Substances Act, citing public health and safety concerns, and the withdrawal of the drug's original petition for decontrol.

Original source language: Federal Register — Justice DepartmentOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News Central Bank Policy News

Related business signals

Regulation & law · 9/14/2026

EPA Lodges Proposed Stipulation and Order of Settlement Under the Toxic Substances Control Act

The U.S. Environmental Protection Agency (EPA) has lodged a proposed stipulation and order of settlement under the Toxic Substances Control Act (TSCA) regarding a specific case.

Read summary →

Regulation & law · 9/14/2026

EPA Lodges Proposed Final Supplemental Consent Decree Under Clean Water Act

The U.S. Environmental Protection Agency (EPA) has lodged a proposed final supplemental consent decree under the Clean Water Act, addressing environmental concerns related to a specific water body.

Read summary →

Regulation & law · 9/14/2026

Bulk Manufacturer of Controlled Substances Application: Cambrex High Point, Inc.

Cambrex High Point, Inc. has submitted an application to the U.S. government to be registered as a bulk manufacturer of controlled substances, a key step in the production and distribution of certain medications. The company is seeking to manufacture basic classes of controlled substances, as outlined in the accompanying SUPPLEMENTARY INFORMATION.

Read summary →

Regulation & law · 9/14/2026

Irvine Labs, Inc. Applies for Controlled Substances Importer Registration

Irvine Labs, Inc. has submitted a request to the government to be registered as an importer of controlled substances, a move that could impact the pharmaceutical industry.

Read summary →

Regulation & law · 9/11/2026

DOJ's EOIR Submits Information Collection Request for Review and Approval

The Executive Office for Immigration Review at the Department of Justice is requesting OMB review and approval for a previously approved information collection, with a request for public comments on the proposed revision and extension.

Read summary →

Regulation & law · 9/8/2026

AndersonBrecon, Inc DBA PCI Pharma Services Seeks Registration as Controlled Substance Importer

AndersonBrecon, Inc DBA PCI Pharma Services has submitted an application to the government to be registered as an importer of controlled substances, a move that could impact the pharmaceutical industry.

Read summary →